Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
Acer Therapeutics (Nasdaq: ACER) announced participation at the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. The management team will present on April 15, 2021, at 11 a.m. Eastern Time and will also host one-on-one investor meetings. Acer focuses on developing therapies for serious rare diseases, with several products in its pipeline, including ACER-001 for metabolic disorders and EDSIVO™ for vascular Ehlers-Danlos syndrome. The company seeks to address significant unmet medical needs in the healthcare sector.
- None.
- None.
NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming 20th Annual Needham Virtual Healthcare Conference April 12-15, 2021.
| Conference: | 20th Annual Needham Virtual Healthcare Conference | |
| Format: | Virtual presentation and one-on-one meetings | |
| Presentation: | April 15, 2021 | |
| Time: | 11 a.m. Eastern Time | |
| Webcast: | https://acertx.com/investor-relations/events-presentations/ |
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the U.S. FDA. On March 19, 2021, Acer entered into a Collaboration and License Agreement with Relief Therapeutics for worldwide development and commercialization of ACER-001. For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
What is Acer Therapeutics' presentation schedule at the Needham Conference?
When is the 20th Annual Needham Virtual Healthcare Conference?
Where can I find the webcast for Acer's presentation?
What therapies is Acer Therapeutics developing?
What is the stock symbol for Acer Therapeutics?
